Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist on hematopoiesis in sublethally y-irradiated mice
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00049995" target="_blank" >RIV/00216224:14110/11:00049995 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1016/j.biopha.2011.04.033" target="_blank" >http://dx.doi.org/10.1016/j.biopha.2011.04.033</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.biopha.2011.04.033" target="_blank" >10.1016/j.biopha.2011.04.033</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist on hematopoiesis in sublethally y-irradiated mice
Popis výsledku v původním jazyce
Mouse hematopoiesis, suppressed by a sublethal dose of ionizing radiation, was the target for combined therapy with a cyclooxygenase-2 (COX-2) inhibitor meloxicam and an adenosine A3 receptor agonist IB-MECA. The drugs were administered in an early postirradiation treatment regimen: meloxicam was given in a single dose 1 hour after irradiation, IB-MECA in two doses 24 and 48 hours after irradiation. Treatment-induced changes in several compartments of hematopoietic progenitor and precursor cells of thebone marrow were evaluated on day 3 after irradiation. Values of hematopoietic progenitor cells for granulocytes/macrophages and erythrocytes (GM-CFC and BFU-E, respectively), as well as those of proliferative granulocytic cells were found to be significantly higher in the mice treated with the drug combination in comparison to irradiated controls and attained the highest increase factors of 1.6, 1.6, and 2.6, respectively.
Název v anglickém jazyce
Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist on hematopoiesis in sublethally y-irradiated mice
Popis výsledku anglicky
Mouse hematopoiesis, suppressed by a sublethal dose of ionizing radiation, was the target for combined therapy with a cyclooxygenase-2 (COX-2) inhibitor meloxicam and an adenosine A3 receptor agonist IB-MECA. The drugs were administered in an early postirradiation treatment regimen: meloxicam was given in a single dose 1 hour after irradiation, IB-MECA in two doses 24 and 48 hours after irradiation. Treatment-induced changes in several compartments of hematopoietic progenitor and precursor cells of thebone marrow were evaluated on day 3 after irradiation. Values of hematopoietic progenitor cells for granulocytes/macrophages and erythrocytes (GM-CFC and BFU-E, respectively), as well as those of proliferative granulocytic cells were found to be significantly higher in the mice treated with the drug combination in comparison to irradiated controls and attained the highest increase factors of 1.6, 1.6, and 2.6, respectively.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
BO - Biofyzika
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/GA305%2F08%2F0158" target="_blank" >GA305/08/0158: Aktivace adenosinových receptorů kombinovaná s inhibicí cyklooxygenázy v modulaci zářením vyvolaného poškození kostní dřeně</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomedicine & Pharmacotherapy
ISSN
0753-3322
e-ISSN
—
Svazek periodika
65
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
IE - Irsko
Počet stran výsledku
5
Strana od-do
427-431
Kód UT WoS článku
000296961900006
EID výsledku v databázi Scopus
—